Wall Street Is Ignoring Bristol Myers Squibb's Cash Machine -- and That's an Opportunity for Income Investors

Bristol Myers Squibb, a pharmaceutical company with roots dating back to the mid-1800s, is currently facing patent expirations that have caused some investor concerns. However, the company has transformed into a dividend powerhouse, yielding a robust 4%, significantly higher than the average pharma stock yield of 1.4%. This makes Bristol Myers Squibb an appealing opportunity for long-term income investors.

The company's success hinges on its growth portfolio, which is driving substantial cash flow. Despite the looming patent expirations on some of its older drugs, Bristol Myers Squibb's revenues from its growth portfolio have been on the rise. This diversified portfolio includes a dozen drugs, generating $7.6 billion in revenue and showing strong revenue growth.

While the legacy portfolio, which comprises drugs nearing the end of their patent protection, is a concern for investors, Bristol Myers Squibb has navigated similar transitions in the past. The company's strong legacy portfolio revenues, currently around $5.4 billion, and the robust growth of its growth portfolio, amounting to $7.6 billion, contribute to its overall resilience and appeal.

The real challenge lies in the company's top-selling drug, Eliquis, which accounts for a significant portion of the legacy portfolio's revenue. Once Eliquis loses patent protection, there is considerable pressure on Bristol Myers Squibb to find a replacement. However, the company's diversified growth portfolio provides a solid foundation for continued income generation and investment opportunities.